Propofol Reduces Spinal Motor Neuron Excitability in Humans

Manabu Kakinohana, Tatsuya Fuchigami, Seiya Nakamura, Tetsuya Kawabata, Kazuhiro Sugahara

Anesthesia & Analgesia · 2002 · 42 citations · 10 references

Concepts

Abstract

Although substantial depression of transcranial motor evoked potential (tc-MEP) amplitude occurs after an induction dose of propofol (1), it is not clear whether this suppression is due to effects of propofol at corticospinal neurons (supraspinal level) or spinal motor neurons (spinal level). We studied the effect of propofol on spinal motor neuron excitability by measuring the F wave, which is the late muscle potential after stimulation of a peripheral motor nerve (2). Stimulation of a peripheral motor axon leads to simultaneous orthodromic and antidromic action potentials. The orthodromic potential quickly leads to a compound muscle action potential known as the “M wave.” Concurrently, the antidromic action potential is conducted back to the soma of the neuron, where it induces a “backfire,” or recurrent discharge, that is orthodromically conducted to innervated muscle, producing a second wave of muscle action potential, the F wave (3). The F wave is useful in evaluating spinal motor neuron excitability. F wave analysis is a noninvasive electrophysiologic technique that can measure the effect of anesthetics on the spinal cord (2). A human study (4) showed that 2 mg/kg of IV propofol, but not 1 mg/kg of IV ketamine or 5 μg/kg of IV fentanyl, decreased F-wave persistence; this suggests that propofol can reduce spinal motor neuron excitability in humans. In this study, we investigated in humans whether changes in spinal motor neuron excitability correlate with the predicted propofol concentration (Cpt) achieved by a target-controlled infusion system. Methods The protocol for this study was approved by the local ethics committee, and written informed consent was obtained from study participants. Subjects were eight adult patients (five men and three women) aged 30–49 yr (38 ± 6 yr, mean ± sd) who were classified as ASA physical status I or II and who underwent elective lower-extremity surgery under epidural anesthesia supplemented with propofol. Patients with any history of neuromuscular disease were excluded. Premedication consisted of atropine 0.5 mg given IM 30 min before the epidural catheter insertion. The usual monitors were used in the operating room. After baseline values were recorded, epidural catheters were inserted 3 cm into the epidural space at the L3-4 interspace. After 3 mL of a 1.5% lidocaine test dose containing 15 μg of epinephrine, an additional 5–6 mL of 1.5% lidocaine with 1:200,000 epinephrine was injected. The extent of dermatomal analgesia by pinprick and cold insensitivity was assessed every 5 min until sensory blockade was confirmed. Epidural infusion of 1.5% plain lidocaine at 4 mL/h was begun and continued until the end of surgery. Spinal motor neuron excitability was determined by measuring the left median nerve F wave. A baseline F wave was evoked with supramaximal electrical stimuli (8.0–14.0 mA) and recorded by using Neuropack Σ® (Nihon Kohden Co., Tokyo). Two surface recording electrodes were placed 4–5 cm apart over the abductor pollicis brevis muscle. Supramaximal stimuli of 0.1 ms duration were applied percutaneously to the median nerve at the wrist joint with a stimulation rate of 1.0 Hz. To distinguish F waves from background noise, we accepted only appropriately timed (25–35 ms after electrical stimuli) deflections from baseline with an amplitude of at least 50 μV (Fig. 1). The filter setting was 100–1500 Hz to remove background noise. To determine F-wave persistence (number of measurable F waves divided by the number of electrical stimuli), a series of 16 stimuli was delivered at an interstimulation interval of 1 s.Figure 1: Original recording of M and F waves before propofol infusion.All patients received a computer-controlled infusion of propofol by using an Apple® Machintosh™/Power Macintosh™ (Apple, Inc., Cupertino, CA) computer that was loaded with three-compartment propofol pharmacokinetic data (5). A target-controlled infusion (Graseby® 3500 infusion pump) was used to rapidly attain and maintain a sequentially increasing Cpt from 0.5 to 1.8 μg/mL. Blood pressure was supported to maintain mean arterial blood pressure values of no more than 75% of preanesthetic values by using IV lactated Ringer’s solution. ETco2 was continuously monitored through the face mask, and, if necessary, mask ventilation was given to maintain ETco2 at 40 ± 3 mm Hg. After the baseline preanesthesia F wave was recorded, Cpt was increased stepwise to 0.5, 0.8, 1.0, 1.3, 1.5, and 1.8 μg/mL in all patients after an F wave was evoked at each concentration. Each Cpt was maintained for 5 min after the effect-site concentration was achieved, and then the F wave was recorded. The average F-wave persistence at Cpt was calculated. Dunnett’s test was used for analysis of variance before and after propofol administration. Probability values <0.05 were considered significant. Data from the plasma concentration-response curves were analyzed, and ICpt50 and ICpt95 were calculated as the Cpt that produced 50% and 95% inhibition of the baseline, respectively. Results The peak block height was between L1 and T10 in all patients. At a Cpt of 0.5 μg/mL, no patient showed a change of consciousness, but all patients were relaxed and comfortable at a Cpt of 1.0 μg/mL. A Cpt of 1.5 μg/mL produced a sedative state, with sustained ability to respond to verbal stimuli. No blood pressure changes >25% of baseline were observed throughout the study period, nor was mask ventilation required. One patient, at a Cpt of 1.8 μg/mL, required a jaw-thrust maneuver to maintain an adequate airway. The M-wave amplitude did not change in any patient during this study. The baseline F-wave persistence (67.2% ± 17.9%) decreased to 29.5% ± 14.1% (P < 0.01) at a 1.0 μg/mL Cpt (Fig. 2). Propofol produced a Cpt-dependent reduction of F-wave persistence. The ICpt50 and ICpt95 were 1.04 μg/mL (95% confidence interval, 0.93–1.20) and 1.95 μg/mL (95% confidence interval, 1.54–2.46), respectively (Fig. 3).Figure 2: Significant decrease of F-wave persistence at a predicted propofol concentration (Cpt) of >1 μg/mL. Data are expressed as mean ± sd. **P < 0.01 compared with preanesthetic level.Figure 3: Concentration (predicted propofol concentration; Cpt)-response curve of the suppressive effect of propofol on F-wave persistence. The Cpt values that produced 50% (ICpt50) and 95% (ICpt95) inhibition of the baseline were 1.04 μg/mL (95% confidence interval, 0.93–1.20) and 1.95 μg/mL (95% confidence interval, 1.54–2.46), respectively.Discussion This study demonstrates that a Cpt of >1.0 μg/mL significantly reduces F-wave persistence in a Cpt-dependent manner and that ICpt50 and ICpt95 are 1.04 and 1.95 μg/mL, respectively. Because propofol did not decrease M-wave amplitude evoked by supramaximal electrical stimulation, F-wave suppression did not result from the effects of propofol on the neuromuscular junction or muscle. Our data suggest that propofol at clinical doses decreases motor neuron excitability in humans. In recent years, computer-controlled infusion devices have been developed to enhance control of IV drug administration (6). A good statistical relationship was found between measured blood propofol concentrations and the corresponding computer predictions (7), by use of the pharmacokinetic variables derived by Marsh et al. (5). In our study, at a Cpt of 0.5–1.0 μg/mL, all patients could be aroused with verbal stimuli. At a Cpt of 1.5–1.8 μg/mL, the patients were sedated. These clinical effects are consistent with the concentration-response effects described by Shafer et al. (8) Although blood propofol concentrations were not determined in this study, we believe that the Cpt values accurately predicted blood concentration. The mechanism by which anesthetics depress spinal motor neuron excitability is unknown. Rampil and King (9) hypothesized that the reduction of motor neuron excitability by inhaled anesthetics might be due to hyperpolarization. Propofol potentiates γ-aminobutyric acid type A receptor channels (10), and this can depress spinal motoneuron excitability. By using a section of spinal cord from adult turtles, Guertin and Hounsgaard (11) demonstrated that propofol reduced the excitability of spinal motor neurons by suppressing the plateau potentials mediated by L-type calcium channels. These effects are likely to contribute to the suppression of spinal motor neuron excitability by propofol. Our results suggest that tc-MEP in response to single-shock stimulation of the motor cortex may not be well preserved at a Cpt of larger than 2 μg/mL because of the inhibition of spinal motor neuron excitability. Kajiyama et al. (12) suggested that when tc-MEP is monitored under propofol anesthesia, it is important to control anesthetic conditions for reliable measurements. Propofol, which can provide easy titration of anesthetic depth (13), may be useful for general anesthesia when tc-MEP should be monitored, and in that case, anesthesiologists should be aware of the suppression of spinal motor neuron excitability at anesthetic levels of Cpt. In conclusion, we demonstrated that propofol can suppress F-wave persistence in humans in a Cpt-dependent manner. Our data indicate that depression of spinal motor neuron excitability occurs at anesthetic levels of Cpt.

References

10